Principles and use of anti-CTLA4 antibody in human cancer immunotherapy Journal Article


Authors: Peggs, K. S.; Quezada, S. A.; Korman, A. J.; Allison, J. P.
Article Title: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
Abstract: Cytotoxic T lymphocyte antigen-4 has become recognized as one of the key negative regulators of adaptive immune responses, having a central role in the maintenance of peripheral tolerance and in shaping the repertoire of emergent T cell responses. Concurrent recognition of the potential importance of inhibitory immune regulators in limiting antitumor responses, either as a result of chronic antigenic stimulation or the self-nature of many tumor-selective target antigens, has led to the development of cytotoxic T lymphocyte antigen-4-blocking antibodies as therapeutic anticancer agents. Following extensive preclinical modeling, these agents have entered clinical trials, where they are showing encouraging activity in heavily pretreated patients with advanced-stage disease, particularly with melanoma or renal carcinoma. Finding ways to dissociate antitumor activity from adverse immune events should enable actualization of their therapeutic potential in the coming years. © 2005 Elsevier Ltd. All rights reserved.
Keywords: clinical trial; review; hepatitis; nonhuman; cancer staging; neoplasms; t lymphocyte; animals; interleukin 2; cancer immunotherapy; melanoma; ovary cancer; gastrointestinal symptom; kidney carcinoma; immunoregulation; rash; antibodies, monoclonal; immune response; immunotherapy; antigens, neoplasm; cell migration; tumor immunity; colitis; antigens, cd; colon carcinoma; cytotoxic t lymphocyte antigen 4; antibodies, neoplasm; antigens, differentiation; uveitis; antigen-antibody reactions; hypophysitis; models, immunological; antigen function
Journal Title: Current Opinion in Immunology
Volume: 18
Issue: 2
ISSN: 0952-7915
Publisher: Elsevier Inc.  
Date Published: 2006-04-01
Start Page: 206
End Page: 213
Language: English
DOI: 10.1016/j.coi.2006.01.011
PUBMED: 16464564
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 158" - "Export Date: 4 June 2012" - "CODEN: COPIE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Karl Stuart Peggs
    11 Peggs
  2. James P Allison
    130 Allison
  3. Sergio A Quezada
    14 Quezada